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Abstract: Until now, decisions about how to allocate ART
have largely been based on maximising the therapeutic
benefit of ART for patients. Since the results of the HPTN
052 study showed efficacy of antiretroviral therapy (ART)
in preventing HIV transmission, there has been increased
interest in the benefits of ART not only as treatment, but
also in prevention. Resources for expanding ART in the
short term may be limited, so the question is how to
generate the most prevention benefit from realistic
potential increases in the availability of ART. Although
not a formal systematic review, here we review different
ways in which access to ART could be expanded by
prioritising access to particular groups based on clinical or
behavioural factors. For each group we consider (i) the
clinical and epidemiological benefits, (ii) the potential
feasibility, acceptability, and equity, and (iii) the afford-
ability and cost-effectiveness of prioritising ART access for
that group. In re-evaluating the allocation of ART in light
of the new data about ART preventing transmission, the
goal should be to create policies that maximise epidemi-
ological and clinical benefit while still being feasible,
affordable, acceptable, and equitable.
Introduction
There has been a rapid expansion in access to antiretroviral
therapy (ART) over the past decade, especially in the countries
with the highest burden of HIV. At the end of 2010, an estimated
6.7 million people were on ART globally, an increase of over 1.4
million from the previous year, but around 7.5 million people are
still in need of treatment based on current World Health
Organization (WHO) guidelines [1]. Until now, decisions around
how to allocate ART have been based on maximising the
therapeutic benefit of ART for patients, within the constraints of
limited financial and health care system resources [2]. This has led
to ART access being prioritised for those with the lowest CD4 cell
counts (and patients with active tuberculosis [TB]) [3].
The HPTN 052 study [4] demonstrated that earlier ART
initiation can reduce heterosexual HIV transmission [5]. This
finding suggests that future expansions of ART access should seek
to maximise not only the therapeutic but also the prevention
benefits of treatment. Currently, constrained resources and
capacity for HIV treatment and prevention [6–8] make it
unfeasible to immediately provide ART for all people living with
HIV, even if this was the optimal epidemiological and therapeutic
strategy and was widely accepted by communities. However, as
increasingly high levels of access under current guidelines are
achieved in coming years, the recent information about the
prevention benefit of ART has inspired renewed discussion about
whether and how to incrementally expand access to treatment to
subgroups that will differentially benefit from the preventive and
therapeutic features of ART, especially in sub-Saharan Africa,
where the burden of HIV is greatest.
Candidate priority groups for early treatment are defined by
both clinical and behavioural criteria. Potential clinical criteria for
providing early treatment include the following: incrementally
increasing the CD4 cell count threshold for treatment eligibility,
immediate treatment for those with high set-point viral load,
immediate treatment for pregnant women, and immediate
treatment for those with TB coinfection. Behavioural risk groups
that have been proposed for early treatment include HIV-
serodiscordant couples, female sex workers (FSWs), men who
have sex with men (MSM), and people who inject drugs (PWID).
Expanding access to treatment for each of these subgroups is
evaluated here according to (i) clinical and epidemiological
benefits, (ii) potential feasibility, acceptability, and equity, and
(iii) affordability and cost-effectiveness (Box 1).
This article is not a systematic literature review of all clinical,
epidemiological, and policy implications of alternative options for
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expanding HIV treatment programmes. Rather, it represents an
organised collection of expert opinions, literature reviews, and
multidisciplinary discussions. Following the publication of the
HPTN 052 results and the US President’s Emergency Plan for
AIDS Relief (PEPFAR) Scientific Advisory Board recommenda-
tions for PEPFAR HIV treatment programmes [2], experts in the
field of HIV epidemiology, mathematical modelling, and HIV
policy were convened in an HIV Modelling Consortium (http://
www.hivmodelling.org) meeting in November 2011 to discuss the
potential impact of expanded HIV treatment in sub-Saharan
Africa. Following from this meeting, this review focuses on the
biological and behavioural factors that determine the potential
impact of various ART prioritisation options on transmission,
morbidity, and mortality, as well as the factors affecting feasibility,
affordability, acceptability, cost-effectiveness, and health systems
interactions. These include the relative size of the priority group,
anticipated ease of identification and recruitment of the priority
group, treatment uptake, adherence and loss to follow-up, ethical
challenges, and technical and human resources required.
Potential Prioritisation Groups for ART Expansion
CD4 Cell Count
CD4 Cell Count
As many low- and middle-income countries are moving towards
adoption of the WHO guidelines of providing treatment for all
HIV-infected individuals with CD4 cell counts less than 350 cells/ml
[3], one natural strategy for increasing the prevention benefit of
treatment is to further increase the threshold of eligibility to those
with CD4 counts less than 500 cells/ml. Current US treatment
guidelines recommend initiation of treatment for asymptomatic
HIV-infected individuals with CD4 counts between 350 and 500
cells/ml [9], and European guidelines suggest that treatment should
be considered at this point [10]. Observational and clinical trial data
that link transmission events confirm that heterosexual transmis-
sions occur from asymptomatically infected individuals with CD4
counts between 350 and 500 cells/ml [5,11], and the HPTN 052
study demonstrated a 96% reduction in transmission associated
with treatment initiation at a CD4 cell count between 350 and 550
cells/ml compared to delaying treatment until CD4 count was below
250 cells/ml [5]. However, compared to other CD4 strata,
individuals with CD4 counts between 350 and 500 cells/ml have
the lowest transmission rates [11] (Figure 1), suggesting that
expanding treatment to this group without considering other
biological or behavioural transmission risk factors may be the least
efficient strategy for prioritising treatment for prevention.
The magnitude of the overall long-term additional therapeutic
benefit of providing treatment at CD4 count above 350 cells/ml is
uncertain. A collaborative analysis of observational data found
that deferring treatment initiation from between 351 and 450
cells/ml to between 251 and 350 cells/ml increased the hazard of
AIDS or death by 28% [12], and the HPTN 052 trial found that
delaying treatment until CD4 count was lower than 250 cells/ml
was associated with a 41% increased hazard of adverse clinical
outcome [5]. However, the potential benefits of early treatment
need to be weighed against the potential toxicities of ART and
negative effects on quality of life [9]. Earlier treatment initiation
may also be associated with poorer adherence or retention in care
[13], which can lead to increased risk of drug-resistant virus. More
robust data about the clinical benefit of earlier treatment and
patients’ retention in care when treatment is initiated earlier are
expected from the START trial [14].
Both the cost and epidemiological impact of expanding
eligibility for ART to those with CD4 counts up to 500 cells/ml
will largely be determined by the number of additional people on
treatment. Cross-sectional data from sub-Saharan Africa suggest
that between 20% and 25% of HIV-infected people have CD4
counts between 350 and 500 cells/ml [15]. Based on the Joint
United Nations Programme on HIV/AIDS estimate of approx-
imately 19.8 million adults infected in sub-Saharan Africa [16],
increasing the CD4 threshold would add between 4 and 5 million
to the 10 million people currently still in need of treatment.
However, even with a change in the threshold at which patients
are considered eligible for treatment, the numbers expected to
initiate treatment at high CD4 counts will be low without
improvements in frequency of testing and retention in pre-ART
care [17]. Surveillance of HIV testing programmes in a township
near Cape Town, South Africa, found that amongst individuals
accessing voluntary counselling and testing, 66% of those testing
HIV-positive already had CD4 cell counts below 350 cells/ml [18].
Box 1. A Breakdown of Questions Related to
the Impact, Feasibility, Affordability, and
Acceptability of Expanded ART Provision
Epidemiological Impact
N What is the incremental effectiveness of the expanded
ART programme for averting new HIV infections, relative
to the existing HIV prevention and treatment pro-
gramme?
N What is the likelihood of behavioural risk substitution
that could undermine prevention benefits?
Clinical Impact
N What is the incremental effectiveness of expanding ART
for averting HIV-related morbidity and mortality, relative
to the existing modes of ART delivery?
N What is the potential impact of expanded access to ART
on the acquisition and transmission of drug resistance?
Affordability and Cost-Effectiveness
N What size is the additional priority group?
N What is the expected start-up cost of the expanded ART
programme?
N How would the programme costs accumulate over time?
N Would the programme be cost-effective compared to
accepted international benchmarks, and relative to
alternative HIV prevention methods?
Feasibility
N What infrastructure and human resources does the
expanded ART programme require?
N How would the prioritisation for a particular group be
operationalized?
N What is the expected adherence and retention in care for
the additional priority group?
Acceptability
N Would the expanded ART programme violate principles
of health ethics or human rights?
N Would the expanded ART programme be acceptable to
the newly eligible priority group, communities, and
decision-makers?
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Another testing-related problem is that within-patient variability in
CD4 cell count can be very high [19], such that the CD4 count
from a single test could be an unreliable indicator of transmission
risk and clinical need [20,21]. Moreover, HIV-infected individuals
who are feeling healthy may decline the option to initiate
treatment [22], a challenge likely to be exacerbated under earlier
treatment eligibility at high CD4 counts. Earlier access to ART
would, on the other hand, also reduce the number of patients
needing pre-ART care, the phase at which retention is the poorest,
according to a systematic review of retention in HIV care in sub-
Saharan Africa [17].
Steadily increasing the CD4 threshold for treatment eligibility as
further resources become available may be viewed as the most
equitable and acceptable strategy for allocating additional
treatment, considering that treatment eligibility has long been
based on a CD4 criterion, but while resources for treatment
continue to be constrained, expanding treatment access beyond
current clinical guidelines based on an increasing CD4 criterion is
unlikely to be the most efficient route to maximising the
epidemiological or clinical benefit of ART.
Viral Load
Untreated asymptomatic HIV infection is characterised by the
viral load fluctuating around a steady level, called the set-point
viral load (SPVL) [23]. Individuals vary considerably in SPVL;
values are approximately log-normally distributed with standard
deviation 0.75 log10 units, such that the 95% range spans a 1,000-
fold variation in SPVL [24]. SPVL has proven one of the more
robust predictors of infectiousness [11,25–28]. In a recent study
amongst serodiscordant couples [28], the transmission rate in
couples with index individuals with viral load in the range 100,000
to 1,000,000 copies/ml of blood was estimated to be 5.6 per 100
person-years at risk (95% confidence interval: 4.0 to 7.6), while the
transmission rate for index individuals with viral load in the range
100 to 1,000 copies/ml was estimated at 0.8 per 100 person-years
(0.4 to 1.5). Thus, a 100-fold difference in viral load translates to a
7-fold variation in infectiousness, although this relationship is
highly nonlinear [11,25–28]. As it becomes easier to measure viral
loads in the field, with point-of-care tests in development (e.g.,
[29]), it becomes reasonable to ask whether prioritising further
ART expansion for individuals with high viral load would be an
effective, efficient, and affordable strategy.
While individuals with high SPVL are more likely to effectively
transmit the virus, they also tend to progress from asymptomatic
infection to disease more quickly than those with low SPVL [30].
To estimate how much individuals with differing SPVL contribute
to the epidemic, their transmission potential can be calculated as
the product of their biological infectiousness and duration of
Figure 1. HIV transmission and mortality by CD4 count. (A) HIV transmission rate per 100 person-years (PYs) by CD4 count for the infected
partner in discordant couples enrolled in a randomized controlled trial of acyclovir [11]. (B) Mortality rate by CD4 category in ART-naı¨ve HIV-positive
individuals enrolled in research cohorts in West Africa [132]. In both panels, the width of the bars represents the proportion of ART-naı¨ve HIV-positive
15- to 64-year-olds by CD4 count in a nationally representative household survey in Kenya [15].
doi:10.1371/journal.pmed.1001258.g001
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infection [24] (Figure 2). Compared to individuals with interme-
diate SPVL, individuals with very high SPVL may contribute less
to the epidemic, because they progress to advanced disease and
death very quickly and thus have fewer opportunities to infect
others.
Consequently, prioritised ART expansion for individuals with
very high viral loads may not provide greater long-term prevention
benefits than expanded access for a comparably large random
fraction of the untreated population. The principal frailty in this
conclusion comes from multiplying infectiousness and duration of
asymptomatic infection from different studies. However, this
conclusion is robust to parametric assumptions, to assumptions
about the sexual network, and to including heightened infectious-
ness in early- and late-stage untreated infection [24,31].
While the epidemiological benefit of expanded ART access for
individuals with very high SPVL may be limited, targeting these
individuals for rapid ART initiation may offer substantial clinical
benefits. ART prioritisation for people with very high SPVL could
be expensive to implement, as viral load screening and follow-up
would require substantial resources. How this form of prioritisa-
tion would affect the number of patients eligible for treatment is
not clear: a recent analysis of HIV-1 RNA viral load data from two
general population cohorts in Botswana suggested that 24%–28%
and 14%–18% of HIV-infected, treatment-naı¨ve individuals
(n= 1,286) had viral load levels greater than 50,000 and 100,000
copies/ml, respectively [32], but it is unclear how many of these
individuals were not eligible under current CD4-based ART
initiation guidelines.
Pregnant Women
Existing guidelines for the prevention of mother-to-child
transmission (PMTCT) recommend that pregnant women with
CD4 counts higher than 350 cells/ml take an antiretroviral drug
course from the 14th week of pregnancy until one week after
delivery (Option A) or until one week after breastfeeding has
finished (Option B) [33]. A new option ‘‘B+’’ has been proposed,
in which pregnant women would be eligible to immediately initiate
lifelong ART regardless of HIV disease stage, TB disease status, or
CD4 count [34]. The cost and epidemiological impact of
expanding ART to all pregnant women will vary between settings
with different patterns of fertility, sexual behaviours, and existing
ART programmes.
The potential HIV prevention impact of option B+, beyond
PMTCT, would be low if many infected pregnant woman are in
stable relationships with partners who are already infected. Data
from Demographic and Health Surveys in Lesotho, Malawi, and
Kenya indicate that more than half of married, cohabiting
partners of HIV-infected pregnant women are HIV-infected (83%
[10/12] in Lesotho, 54% [20/37] in Malawi, and 50% [6/12] in
Kenya) [35–37]. However, for serodiscordant couples, the female-
to-male transmission rate may be more than twice as high during
pregnancy as during non-pregnant periods [38]. Whether ART
initiation during pregnancy would effectively override this risk
elevation is questionable, given the lag time of up to five months
between ART initiation and viral load suppression [39].
The number of additional people who would be on treatment
with this prioritisation strategy depends on several factors. The
crude birth rate (and hence the incidence of pregnancy) varies
greatly across sub-Saharan Africa, even within subregions: from as
high as 46.5 childbirths per 1,000 people per year in Zambia to
less than half this rate (22.9/1,000 individuals/year) in the
neighbouring country of Botswana [40]. However, overall, the
difference between the number of HIV-infected pregnant women
that would be ART-eligible under PMTCT option B+ and the
number eligible under current ART initiation guidelines may be
small because of the effect of haemodilution on CD4 cell count.
Haemodilution, a normal physiological phenomenon during
pregnancy, temporarily reduces CD4 cell count, meaning that
many pregnant HIV-infected women become eligible for treat-
ment on the basis of CD4 count during pregnancy. In a
prospective cohort study of 324 HIV-infected pregnant women
from Abidjan, Cote d’Ivoire, 48.3% (157/325) had CD4 counts
less than 350 CD4 cells/ml at 32 weeks of gestation, yet this
fraction decreased to 28.9% (94/325) one month postpartum [41].
The implication for Cote d’Ivoire is that only just over 10,000
additional women would initiate ART if immediate treatment was
expanded to all pregnant women regardless of CD4 count, and
ART coverage in women, in the first year of the intervention,
would increase only from 39% to 42% [42].
HIV-positive pregnant women are a priority group that is
relatively easy to identify, because of the high uptake of antenatal
care (ANC) in most populations, with associated HIV counselling
and testing, even in resource-limited settings. Several studies
reported very high acceptance of provider-initiated HIV counsel-
ling and testing in ANC at several sites across Africa during the
past few years: 99.5% acceptance of testing in Nigeria, 91% in
South Africa, 97% in Ghana, and 99% in Zambia [43–46]. The
acceptance of HIV testing at first ANC visit is still as low as 69.1%
in rural areas of Swaziland and South Africa [47], but provider-
initiated testing and counselling in ANC may be able to raise the
testing uptake by 9.9%–65.6% [48].
Obstacles remain in the linkage between diagnosis in ANC and
long-term ART treatment because of ART refusal and poor
retention. In a recent review, Ferguson et al. found that 38%–88%
of known ART-eligible women in sub-Saharan countries fail to
initiate treatment [49]. Once in treatment, retention among pregnant
women has been found to be no worse than in other population
groups in seven resource-limited countries in sub-Saharan Africa and
Thailand [50]. However, Boyles et al. found that initiating ART
while pregnant is associated with a higher lost-to-follow-up risk
compared with the general population in rural South Africa [51].
Retention challenges faced when expanding ART to pregnant
women regardless of CD4 count are likely to be similar to those
currently faced in traditional PMTCT programmes: (1) patients’ not
being prepared for HIV testing and its implications before the ANC
visit; (2) fear of stigma, discrimination, household conflict, or divorce
on disclosure of HIV status; (3) long waiting times at the ANC
facilities; and (4) inability to afford the transport to these facilities [52].
Because expanding access to ART for pregnant women utilises
existing ANC and PMTCT infrastructure for diagnosis and HIV
counselling, the only additional costs associated with this strategy
are additional drug costs for the period between the end of
pregnancy and ART eligibility under other criteria, suggesting
favourable affordability of this ART expansion strategy. Cost-
effectiveness studies of ART in pregnant women have thus far
focused on benefits in terms of PMTCT, and have found that it is
cost-effective as measured against accepted international bench-
marks in a variety of low- and middle-income countries [53,54].
Cost-effectiveness studies of PMTCT option B+ for adult HIV
transmission prevention are still to be conducted. Expanding ART
to all HIV-positive pregnant women may provide additional
maternal health benefits and contribute to the Millennium
Development Goals if ART, PMTCT, and reproductive health
care services are integrated [55,56].
Active Tuberculosis Disease
The provision of ART to all HIV-infected people with active
TB disease, irrespective of CD4 cell count, has been recom-
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Figure 2. The transmission potential of individuals as a function of set-point viral load. (A) Infectiousness (per unit calendar time) and (B)
duration of asymptomatic infection are estimated by fitting to various sources of data as described in [24]. (C) The product of these is the
transmission potential, the average number of people an infected individual is expected to infect over the whole of asymptomatic infection. The
transmission potential measures the relative prevention effect of treatment as prevention targeted to an individual with a given SPVL. Adapted from
Fraser et al. [24].
doi:10.1371/journal.pmed.1001258.g002
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mended by the World Health Organization since 2010 [3], based
on its clinical benefits. In the SAPiT trial, the mortality rate in 429
patients with CD4 cell counts up to 500 cells/ml who initiated
ART during TB treatment was 56% lower (95% confidence
interval: 21%–75%, p= 0.003) than in patients who initiated ART
after completion of TB treatment [57]. However, the coverage of
ART for all HIV-infected people with active TB disease remains
low. In the WHO African Region in 2011, only 59% of TB
patients were tested for HIV, and of those identified to be HIV-
infected, only 42% were on, or started on, ART [58].
The epidemiological benefits of expanding ART to all patients
with active TB disease are unclear. Although there were some
early indications that those with TB disease are more infectious
[59–61], the largest study conducted among HIV-positive people
with incident TB disease indicated that viral load increases by only
a small amount following a TB episode [62], and a more recent
study showed that treating active TB disease in individuals with
CD4 counts greater than 350 cells/ml reduced markers of immune
activation but had no effect on HIV viral load or CD4 count [63].
Therefore, providing ART to TB patients with CD4 counts above
350 cells/ml is likely to have a similar prevention effect on HIV
transmission as treating a random subset of HIV-infected
individuals with a CD4 count above 350 cells/ml.
In high HIV prevalence settings, the proportion of HIV-infected
people with active TB who have CD4 cell counts greater than 350
cells/ml has been estimated to range from 11% to 30% [2].
Assuming a 1% incidence of active TB disease and 50% HIV
prevalence in individuals with incident active TB, this would mean
that for South Africa, around 27,500 to 75,000 extra individuals
would be eligible for ART in the first year of this form of
prioritisation. Given the suppressive effect of ART on TB disease
incidence [64,65], a decreasing number of active TB patients in
need of ART would be expected in the following years. A
modelling study that estimated the impact of the roll-out of annual
HIV testing and immediate ART on TB disease incidence in nine
African countries reported a 21% (range: 10%–31%) reduction in
the cumulative AIDS-related TB disease incidence over the first
five years, and a 48% (range: 37%–55%) reduction in the
incidence of TB disease at five years [64].
Integration of ART provision for all HIV patients, regardless of
TB coinfection status, with TB services may offer a relatively
feasible way to implement an expansion of ART to individuals
with active TB disease. Data from eight countries with a high
burden of HIV-infection-associated TB showed that there were up
to five TB treatment facilities for each ART facility in 2007 [66],
and a study in Tugela Ferry, South Africa, showed that integration
of TB and HIV services was associated with high ART adherence
[67]. However, with this approach it would be critical to
implement adequate infection control to minimise nosocomial
TB infection, and obtaining high TB treatment coverage is
challenged by the difficulty of diagnosing active TB in HIV-
infected patients [68].
Given the clear clinical benefit of ART in TB patients, this
option of ART expansion is likely to be highly acceptable by both
the target group and the general population. For TB patients,
current illness and the prospect of a reduced risk of TB recurrence
are incentives for ART initiation, high adherence, and retention in
care. If implemented successfully, ART expansion to all TB
patients should lead to large gains in healthy person-years of life
and long-term cost savings due to decreased recurrent TB.
Serodiscordant Long-Term Relationships
Stable serodiscordant relationships, in which one partner is HIV-
infected and the other is not, are an identifiable prevention
opportunity, and the continued transmission in such couples during
carefully monitored clinical trials with intensive counselling demon-
strates the need for additional prevention options for this population
[5,11]. Trial and observational data have demonstrated the efficacy
of ART in preventing HIV transmission in stable serodiscordant
heterosexual partnerships [5,11], and recent WHO guidelines for
stable serodiscordant couples already include offering ART to the
HIV-infected partner irrespective of CD4 cell count, in addition to
behaviour change counselling [69]. While the biological efficacy of
the effect of ART on transmission risk should generalise to non-
stable heterosexual partnerships as well, it has been hypothesized
that couples in stable partnerships will be most able to adhere to daily
dosing regimens and therefore achieve the maximum individual-
level benefit [70,71]. Further, it is known that couples in stable
partnerships in which the HIV-infected individual has a high CD4
cell count are likely to conceive (16% per year among discordant
couples [38]); therefore this strategy would incur many of the
maternal and PMTCT-related health benefits described above [33].
The relative epidemiological impact of prioritising early treat-
ment to HIV-infected individuals who have an uninfected long-term
partner will depend primarily on the risk of within-couple
transmission without treatment, and secondarily, on the risk of
onward transmission from the partner to someone else. The risk of
transmission without ART in couples could be relatively low: 1.7
per 100 person-years at risk ([5]; among those with CD4 counts of
350–500 cells/ml: [11]). One model suggests that providing ART to
serodiscordant couples might be expected to avert 21 infections per
1,000 person-years of ART [72]. If the risk of transmission in
couples is actually higher (as has been observed in couples that did
not necessarily know that they were in a discordant partnership
[73], and as assumed by El-Sadr et al. [74]), and if it is assumed that
the infected partner forms many additional partnerships with other
individuals, then it has been estimated that the number of infections
averted per 1,000 person-years of ART could be as high as 77. This
can be compared to 53–159 for providing ART to all individuals
with CD4 cell counts below 350 cells/ml irrespective of partnership
status, and 65–152 if ART is provided irrespective of CD4 cell count
[75]. Thus, prioritising those in stable partnerships for treatment
may not be a more efficient form of prevention than providing the
treatment to the general population without prioritisation.
It is unclear how feasible it would be to preferentially provide
access to ART to those in serodiscordant couples. Only ,8%–
31% of couples were found to be discordant in recruitment to a
clinical trial [76], and other data suggest that the countries with
the highest levels of HIV prevalence tend to have the smallest
numbers of stable serodiscordant couples [77]: only a small
minority (,15%) of infected individuals report being in a stable
partnership with someone known to be uninfected [77]. There are
few opportunities to identify serodiscordant couples in current
health care systems in most settings in Africa, though household
testing interventions may increase opportunities to reach couples
[78]. However, many would question the general acceptability of
an intervention that favours those in stable discordant partnerships
over those in concordant partnerships. Operationally, defining a
consistent criterion for a discordant couple is challenging. In
Kenya, for example, there may be 150,000 individuals that would
be newly eligible to start treatment today under this policy [77],
but many more might claim to be in stable discordant
relationships, or limitations in disclosure in couples could mean
that many fewer would actually start treatment earlier.
Female Sex Workers
Almost one-fifth of the HIV epidemics in sub-Saharan Africa
are classified as concentrated (defined as HIV epidemics with HIV
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prevalence , 1% in the adult population), and many more are not
highly disseminated (43% of epidemics in this region have an adult
HIV prevalence below 3%) [79]. In these settings, FSWs and their
clients are key populations for the transmission of HIV [80–86].
Previous modelling [81,82,87,88] and epidemiological analyses
[89,90] suggest that prioritising interventions for FSWs and their
clients in these settings can substantially reduce HIV transmission
amongst FSWs, and amongst the population as a whole. It
therefore seems natural to consider whether ART eligibility
irrespective of CD4 cell count should be prioritised to FSWs.
A literature review was conducted in PubMed with the search
terms ‘‘(‘‘sex workers’’ or FSW or FSWs or CSW [commercial sex
worker] or CSWs or sexwork*) and HIV and (antiretroviral or
‘‘anti-retroviral’’ or ART or HAART)’’. This produced 67 papers,
of which nine considered ART treatment amongst FSWs, barriers
to accessing care, and risk behaviours following ART initiation
[91–97]. The majority were from sub-Saharan Africa (six of nine),
with three others from Chennai, India, and Vancouver, Canada.
These papers informed the following discussion of ART prioritisa-
tion for FSWs.
In settings with existing and effective non-ART interventions to
prevent HIV transmission amongst FSWs and their clients, the
main questions are to evaluate the potential added prevention
benefits of prioritising ART to FSWs, and the likelihood of risk
substitution (i.e., potential increases in risk behaviours following
ART expansion) [94,98,99]. In settings where behaviour-targeted
interventions have not been fully implemented, the question is
whether these should be scaled up before scaling up ART for
prevention. If expanded access to ART is scaled up for FSWs
following behaviour change interventions, this may increase the
relative impact of ART treatment. For instance, because increases
in condom use could reduce the incidence of new acute HIV
infections, it is possible that such an intervention could temporarily
lead to a smaller proportion of incident infections being due to
early acute infection, and therefore a relatively greater prevention
benefit of ART when provided to those with chronic infection.
Achieving a high preventive benefit from expanding ART to
FSWs depends on initiating and retaining individuals in
programmes. FSWs have generally received lower coverage of
ART, because of factors such as reduced health-seeking behaviour
and the stigmatised nature of sex work [100]. However, numerous
targeted HIV prevention interventions worldwide show that FSWs
can be engaged and recruited into intensive interventions with
high coverage [101–103] and at reasonable cost [104–106].
Emerging data on ART provision amongst FSWs [92,93,95,107]
suggest that FSWs can be successfully initiated on ART in
resource-poor settings; existing interventions could act as an easy
and affordable entry point for increasing ART coverage among
FSWs [93]. However, maintaining high ART adherence among
FSWs remains challenging, leading to poorer outcomes with
respect to CD4 count and suppression of viral load compared to
non-FSWs [93,107]. This is likely to translate into smaller
reductions in infectivity, and greater morbidity or mortality
[93,107,108], and indicates that there would be a particular need
for retention efforts and adherence counselling for this prioritisa-
tion group [96], which could increase the costs of FSW-targeted
ART programmes.
In addition to clinical and behavioural issues, the transient
nature of sex work could affect the potential impact of ART on
transmission, and the subsequent costs. As most FSWs sell sex for
only a few years [109,110], the early phase of acute HIV infection
with high HIV viraemia may make a disproportionately large
contribution to sex-work-driven HIV transmission [111]. Even
with frequent retesting and immediate linkage to care, ART is
likely to be initiated only after this phase, which would reduce the
impact of ART on transmission, and highlights the continued
importance of condom interventions. In addition, the cumulative
costs of immediate ART eligibility for FSWs might grow sharply,
as new FSWs become infected and eligible for ART, and HIV-
infected former FSWs remain on ART after ceasing sex work. This
could result in considerable investment and a suboptimal
allocation of ART in some settings with rapid turnover of sex
worker populations. However, it is possible that ex-FSWs may still
be at greater risk of transmitting HIV than the general population
and so could remain a good target population for ART as
prevention.
Lastly, as has been shown for other HIV prevention interven-
tions, the expected preventive benefit of targeting FSWs with ART
is smaller in generalised epidemics than in concentrated epidemics,
and is reduced in the late phase of an HIV epidemic compared to
the early phase, especially in the short term. However, even in
generalised HIV epidemics, modelling analyses suggest it would be
cost-effective to target FSWs because of their disproportionate
contribution to HIV transmission, although it may not be
sufficient for achieving large and rapid reductions in HIV
transmission in the general population. Conversely, not reaching
high-risk groups such as FSWs may seriously attenuate the impact
of any ART intervention [71,112].
In summary, the decision to target FSWs with ART provision
has to balance the likely heightened costs associated with increased
adherence counselling and monitoring, and outreach to ensure
retention, with benefits of decreased transmission that may be
short-lived in contexts where sex work is transient. However, in
settings where sex work is longer term the impact could be much
greater. In addition, the ethical and social acceptability of giving
prioritised ART access to FSWs needs to be carefully considered
before any FSW-targeted programme is initiated—the benefits to
the population as a whole would need to be clearly determined
and communicated, and proactive monitoring of all ART
provision channels would need to be in place to ensure that the
care of other HIV-infected individuals is not compromised. Drug
resistance should also be monitored, as FSWs on ART may
facilitate the spread of resistance.
Men Who Have Sex with Men and People Who Inject
Drugs
The arguments for expanded access to other key populations,
including MSM and PWID, are similar to those for expanded
access to FSWs. If there is a population that contributes
disproportionately to the number of infections in a population,
and they can be identified and enrolled and retained in care, then
it could be efficient to prioritise ART access to that group.
However, the evidence from the HPTN 052 study that ART
reduces infectiousness was specifically for heterosexual transmis-
sion: the extent to which ART decreases transmission occurring
through homosexual sex or intravenous injection is not known
[113].
Also, for the epidemics in Africa, there is little information
about the population sizes of MSM and PWID, and their
behaviours and contribution to the epidemic, which makes it
hard to formulate firm recommendations about the benefits of
prioritising access to these groups. Several studies in Africa have
been able to recruit MSM [114,115], and it has been estimated
that, in total, transmission among MSM could account for 6%
of new infections in Kenya and up to 21% in some concentrated
epidemics [115], a range that is broadly supported by the Joint
United Nations Programme on HIV/AIDS review of modes of
transmission ([116]; K. K. Case, P. D. Ghys, E. Gouws, J. W.
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Eaton, P. Cuchi, et al., unpublished data]. Meanwhile, in a
global review of injecting behaviour, there were no data (or
estimated prevalence levels) for most African countries [117],
and consequently the estimated number of HIV-infected PWID
was very uncertain, ranging from 26,000 to 572,000 for sub-
Saharan Africa. However, it has been hypothesized that in
particular areas, such as Mombasa and Nairobi in Kenya, a high
frequency of injecting among a growing population of PWID,
coupled with overlapping sexual risk behaviours, has resulted in
a substantial proportion of overall transmission possibly result-
ing from injection [118,119]. There are also indications that
PWID are less likely to access care and treatment services than
others [120], and they have lower adherence [121] and
retention to therapy [122,123], so any ART programme
prioritising ART to this group would presumably have to
contend with these issues.
Discussion
If it could be afforded, all HIV-infected individuals who wanted
to initiate ART should be able to do so. However, resource
constraints, at least in the short and medium term, necessitate
some form of prioritising of HIV treatment through health
policies. These policies should maximise epidemiological and
clinical benefit while still being feasible, affordable, acceptable, and
equitable [124]. To date, this prioritisation has been based
principally on the CD4 cell count of HIV-infected individuals, as a
marker of their immediate clinical need, but with the finding that
Table 1. Likely profile of prevention and clinical impact, affordability, feasibility, and acceptability of alternative options for ART
expansion beyond current guidelines.
Prioritisation
Group
Impact on New
HIV Infections
Impact on HIV-Related
Morbidity and Mortality Feasibility Affordability Acceptability
CD4 cell count
(350–500 cells/ml)
2 (Unlikely to be highly
transmissible, relative to
those at lower CD4 cell
counts or other
prioritisation groups)
? (Clinical trial evidence
expected from START trial,
reporting in 2015; unlikely
to be as efficient as
strategies targeting clinical
need, e.g., high SPVL, TB
coinfection)
+ (Screening utilises already
standard CD4 screening;
reaching high coverage
would likely require efforts to
improve routine HIV testing
at the population level)
2 (Would likely
expand access to
treatment to an
additional 20% of
the HIV-infected
populations)
+ (May be perceived as
the most equitable
option for expanding
access to ART, because
of the history of
determining treatment
need and access based
on CD4 cell count)
Viral load
(SPVL$50,000
copies/ml)
N (Strong evidence from
many discordant studies
that infectiousness
increases with SPVL,
but not dramatically)
+ (Strong evidence from
many seroconverter cohorts
that individuals with high
SPVL progress rapidly to AIDS,
and so may enhance linkage
to care in rapid progressors)
? (Requires development of
point-of-care viral load
testing; many prototypes,
but none validated yet)
? (Cost of point-
of-care viral load
testing is unknown)
? (May prove
controversial if not
backed by evidence for
direct clinical benefit)
Active TB
disease
2 (Likely to have the
same impact on HIV
transmission as reaching
a subset of HIV-infected
individuals with CD4
cell counts between
350 and 500 cells/ml)
+ (Much greater impact
on morbidity and
mortality than treating
many other groups)
+ (Can be integrated with
existing TB services;
adherence/retention to ART
may be higher because of
current illness and the
prospect of a reduced risk
of TB recurrence)
+ (Relatively small
group, compared with
individuals with CD4
350–500 cells/ml; large
reduction in mortality
suggests targeting TB
patients may be more
cost-effective than
other groups)
+ (Given the clear clinical
need, likely to be highly
acceptable to both the
target group and the
general population)
Pregnant
women
? (Potential reductions
in maternal orphanhood
and potential to
prevent paediatric HIV
transmission; estimates
of the impact on
heterosexual HIV
transmission are yet
to be produced)
+ (Impact mainly on
morbidity and mortality
of newborns with
HIV-positive mothers)
+ (Targets are easy to identify
via existing ANC; testing
uptake is high in some areas
and can be increased by
provider-initiated service;
contrary results are found on
retention)
+ (Increment of newly
identified target
patients is not big;
infrastructures and
staff that already exist
favours the
affordability)
+ (May be better
accepted by patients if
initiated by ANC
provider)
Serodiscordant
couples
2 (Likely fewer
infections averted per
person-year of ART
than allocation to those
with multiple partners)
? (Marginal therapeutic
benefit of ART initiation
at CD4 .350 cells/ml
not certain)
+ (In some settings couples
hard to find; trial data indicate
discordant couples are a highly
motivated population with
good adherence to pill-taking
regimes and retention in care)
? (Minority of infected
individuals in stable
discordant couples,
but uptake unknown)
? (Unclear if it is socially
acceptable for those
with stable partners to
receive preferential
access)
Sex workers + (Elevated HIV
transmission risk in
many settings likely to
result in large number
of HIV infections
averted per year
on ART)
? (May be more modest
than other groups because
limited data suggest that
they have lower adherence
and worse outcomes in
terms of morbidity and
mortality)
+ (Previous FSW-targeted
interventions have
demonstrated feasibility;
limited studies suggest FSWs
are willing to initiate ART;
however, likely to have worse
adherence and retention)
+ (FSWs make up a small
proportion of the female
population, but if sex
work is of short duration,
then there may be a much
larger group of ex-FSWs
that will continue on ART)
? (May not be acceptable
to the wider community;
programmes would
need to show and
emphasise population
benefit)
?, insufficient evidence to warrant definitive decision; +, available evidence suggests this is a beneficial option, compared to the other expansion options; 2, available
evidence suggests this is an unfavourable option, compared to the other expansion options; N, available evidence supports neither that this is a beneficial option nor
that it is an unfavourable option.
doi:10.1371/journal.pmed.1001258.t001
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ART reduces transmission risk, it is important to re-evaluate other
ways in which ART could be allocated. In this article, we have
examined several of the main options for prioritising ART access
and have highlighted the key epidemiological and policy
considerations that should guide decision-making and future
research (summarised in Table 1).
There are some forms of prioritisation that are already
supported by existing guidelines or programmes. In particular,
ART for all individuals with active TB disease has substantial
epidemiological and clinical benefits, and already forms part of
WHO international guidelines. Treatment for pregnant women
irrespective of CD4 cell count, for which the epidemiological
impact is not yet clear, could have advantages in terms of
simplified care for pregnant women and benefits for their children
and partners, and is being implemented in some settings.
Important questions remain regarding all of the options, and
there is a clear need for further data collection. Some knowledge
gaps could be filled shortly, as results are reported from at least
50 projects planned or ongoing to evaluate the impact of ART
and other interventions on HIV- and/or TB-related morbidity
and mortality, HIV incidence and transmission, and risk
behaviour [125]. Almost half of these projects are in sub-
Saharan Africa, and include studies that will test the individual-
and community-level preventive effect of ART provided to
patients with CD4 cell counts between 350 and 500 cells/ml,
those with the highest viral loads, HIV-infected pregnant
women, and HIV-infected partners in serodiscordant couples
[125,126]. In addition, the secondary objectives of many of these
projects are the evaluation of the feasibility, cost, health care
impact, treatment adherence and retention, and social accept-
ability of the interventions. With a large variation in geograph-
ical areas, target populations, and outcome variables, the
combined body of evidence generated by these studies may
begin to address the question of whether and how different
sociodemographic, economic, and epidemiological contexts
influence the impact of ART interventions.
In the short term, the costs of expanding access to ART are
likely to be driven by the size of the groups to whom access is
extended and the costs associated with identifying and reaching
members of these groups. Long-term affordability is likely to
depend on the size of the group as well as reductions in incidence
resulting from the expanded ART programme, the success of
other HIV prevention interventions, and economic nonlinearities
such as economies of scale. Although relative group sizes will vary
from setting to setting, ART expansion to HIV-infected people
with CD4 counts of 350–500 cells/ml or above 500 cells/ml would
likely require the largest programme increase. In contrast, initial
increases required to prioritise ART in FSWs and pregnant
women would most likely be much smaller than for the other
prioritisation options, though cumulative costs would grow as
women started ART during pregnancy or sex work, then
continued on lifelong ART.
Evidence from ART programmes in southern Africa indicates
that high retention in care becomes increasingly challenging as
treatment programmes expand [127]. Affordability and feasibility
are negatively affected not only by larger group size, but also by the
more intensive efforts required to identify eligible people and
maintain high adherence and retention in care. Globally, patients’
health literacy regarding ART adherence remains an important
challenge [128]. On the other hand, there is a rapidly growing body
of strategies and tools to improve retention in care and ART
adherence, including interventions to improve the mental health
(especially treatment of depression) of HIV-positive individuals, and
reminder devices and interactive communication technologies [129].
This review has aimed to highlight some of the key issues and
identify the needs for future studies, and has not provided a direct
quantitative comparison of the impact of alternative prioritisation
strategies in specific settings, which will be a critically important
body of modelling work in the future. To further facilitate a
constructive debate that is meaningful to national decision-makers
and donor organisations, context-specific mathematical models
should be developed that enable head-to-head comparison of
multiple ART expansion options in an internally consistent
manner, that is, with all simulations based on the same data and
assumptions. However, the considerations raised here already
indicate that the impact and feasibility of these alternative forms of
ART allocation are expected to vary substantially between
settings, and there is no single formulation that will be optimal
in all settings. Furthermore, the best strategy will depend on the
relative values assigned to therapeutic benefits, preventative
benefits, and wider societal benefits, such as reducing the number
of orphans and increasing labour force availability. Combined
metrics of impact such as quality-adjusted life years saved or
disability-adjusted life years averted [130] can be used to
understand how preventative and therapeutic benefits are related.
The overall effectiveness of treatment in reducing infectiousness,
as well as the risk of drug resistance [130], is expected to be
crucially dependent on the viral suppression achieved, which is in
turn affected by patterns of adherence. Throughout this analysis,
we have assumed ART has a suppressive effect on HIV
transmission for all patients receiving the treatment. Whilst this
is biologically plausible, we recognise that it is possible that
different groups could behave differently from the HIV-infected
individuals in the HPTN 052 trial and therefore achieve lower
levels of viral suppression and a smaller reduction in infectiousness.
However, there is little information available on levels of viral
suppression for ART, nor on adherence to the treatment regimen.
Finally, we recognise that the issues of expanding access to ART
do not exist in a vacuum. Decisions concerning the implementa-
tion of ART should be scaled—scaling up will have to take place in
the context of the entire portfolio of the HIV response programme
in a particular country, which will include multiple forms of
prevention intervention. Indeed, WHO guidance on the use of
antiretrovirals for prevention is expected to include both pre-
exposure prophylaxis and ART, and we would anticipate that
further strategic advice from normative agencies will increasingly
Key Points
N Discussions about expanded access to ART for HIV
prevention have been focused on one particular
strategy—providing ART to all HIV-infected individuals.
Here we aim to broaden the discussion by considering
the implications of prioritising access to ART according
to clinical and behavioural factors.
N Any recommendation to prioritise particular groups
should consider not only the impact of ART in that
group, including its therapeutic and prevention effects,
but also its feasibility, affordability, and acceptability.
N Some forms of prioritisation—ART for individuals with
active TB and for pregnant women irrespective of CD4
cell count—are already promoted by existing guidelines
or programmes.
N For other prioritisation options, there are currently
insufficient data to make first recommendations, al-
though findings of future studies and further modelling
analyses should contribute to forming policy.
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embrace the full range of possibilities for maximising the health
impact of ART in combination with other interventions [131].
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